Lexicon Pharmaceuticals, Inc. LXRX announced that it has dosed the first patient in a phase IIa study — TELE-ABC — evaluating its sole marketed drug, Xermelo (telotristat ethyl), in patients with biliary tract cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,